Our therapeutic projects involve developing new concepts for nucleic acid-based therapeutics, including using mirtrons for gene silencing, aptamers for binding intracellular targets and promoter decoys. We are keen to work with clinicians to develop nucleic acid-based therapeutics for their specific diseases, taking into account the limitations associated with each disease/target. There are also a number of projects brewing that are looking into where we think nucleic acid therapeutics will head to in the next decade, in anticipation of the maturation of the field.